Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020

Published: January 14, 2021
Abstract Views: 1849
PDF: 984
Supplementary: 127
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Tuberculosis treatment is challenging, especially among people with drug-resistant forms of tuberculosis. The introduction of fully oral modified short treatment regimen has a great potential to shorten duration of treatment, improve safety and ultimately increase treatment success rate. In 2019 Georgia has piloted the modified fully oral shorter treatment regimen in a routine programmatic condition. Our study aimed to evaluate effectiveness and safety of the modified shorter treatment regimen in Georgia among the first 25 consecutively enrolled patients with rifampicin-resistant tuberculosis with proven sensitivity to fluoroquinolone and without prior exposure to second-line tuberculosis drugs. Regimen consisted of 9-month daily administration of bedaquilline, linezolid, levofloxacin, clofazimine and cycloserine. Study patients were enrolled between March-August 2019. We used a national electronic surveillance system, medical records and active TB drug-safety monitoring and management database to extract study related data. The mean age of the study participants was 48 years, 68% were male, 8% were HIV positive, 16% had diabetes and 12% tested positive for hepatitis C infection. The median time to culture conversion among 16 patients who were culture positive at treatment initiation was 1.0 (95% CI: 1.0-2.0) month. Of those, by the end of treatment 15 patients converted to negative. Out of the 25 patients in the study cohort 22 (88%) had successful treatment outcome, one patient (4%) died and two (8%) were lost to follow up. The regimen was largely well tolerated. Three patients (12%) experienced serious adverse events, of which in two cases were possibly related to TB drugs in the regimen. Seven patients developed adverse events of interest in eight instances, including musculoskeletal (twice), psychiatric, gastrointestinal disorders, hepatotoxicity, peripheral neuropathy, cardiotoxicity and myelosuppression (once each). In four patients (16%) the duration of the treatment was extended beyond nine months due to insufficient radiological improvements. Our findings demonstrate that good treatment outcomes are achievable in people with fluoroquinolone-sensitive tuberculosis within routine programmatic conditions using fully oral modified short treatment regimen. The extensive use of fully oral modified shorter treatment regimen in Georgia and other high priority countries in the World Health Organization European Region is warranted.



PlumX Metrics


Download data is not yet available.


WHO. Global tuberculosis report 2019. Geneva: World Health Organization; 2020. Available from: http://www.who.int/tb/publications/global_report/en/
Dadu A, Hovhannesyan A, Ahmedov S, et al. Drug-resistant tuberculosis in eastern Europe and central Asia : a time-series analysis of routine surveillance data. Lancet Infect Dis 2019;3099:1–9.
WHO Regional Office for Europe. Plan to stop TB in 18 High-priority Countries in the WHO European Region, 2007-2015. Copenhagen: World Health Organization; 2007. Available from: https://www.euro.who.int/en/publications/abstracts/plan-to-stop-tb-in-18-high-priority-countries-in-the-who-european-region,-20072015
WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2020 – 2018 data. World Health Organization; 2020. Available from: https://apps.who.int/iris/handle/10665/331530
WHO. The End TB Strategy. Geneva: World Health Organization. 2015. Available from: http://www.who.int/tb/End_TB_brochure.pdf?ua=1
Shringarpure KS, Isaakidis P, Sagili KD, et al. “When treatment is more challenging than the diseaseâ€: A qualitative study of MDR-TB patient retention. PLoS One 2016;11:1–12.
Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis 2020;92:S15–25.
Yang TW, Park HO, Jang HN, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea. Medicine (Baltimore) 2017;96:e7482.
Akkerman O, Aleksa A, Alffenaar JW, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. Int J Infect Dis 2019;83:72–6.
Mbuagbaw L, Guglielmetti L, Hewison C, et al. Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. Emerg Infect Dis 2019;25:936–43.
Hewison C, Bastard M, Khachatryan N, et al. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia. Int J Tuberc Lung Dis 2018;22:766–72.
WHO. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020.
Government of Georgia. National Tuberculosis Program. Tuberculosis Management. National Recommendation for Clinical Practice. 2019.
Assemie MA, Alene M, Petrucka P, et al. Time to sputum culture conversion and its associated factors among multidrug-resistant tuberculosis patients in Eastern Africa: A systematic review and meta-analysis. Int J Infect Dis 2020;98:230-6.
Velayutham B, Nair D, Kannan T, et al. Factors associated with sputum culture conversion in multidrugresistant pulmonary tuberculosis. Int J Tuberc Lung Dis 2016;20:1671–6.
Shibabaw A, Gelaw B, Wang SH, Tessema B. Time to sputum smear and culture conversions in multidrug resistant tuberculosis at university of Gondar hospital, northwest Ethiopia. PLoS One 2018;13:1–15.
Liu Q, Lu P, Martinez L, et al. Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China. BMC Infect Dis 2018;18:1–7.
Qazi F, Khan U, Khowaja S, et al. Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan. Int J Tuberc Lung Dis 2011;15:1556–9.
Borisov S, Danila E, Maryandyshev A, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis : first global report. Eur Respir J 2019;54:1901522.
Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371:723–32.
Gler MT, Vija S, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151–60.
Zhurkin D, Gupta R, Gadoev J, et al. Effectiveness and safety of bedaquiline-containing regimens among adults with multidrug- or extensively drug-resistant pulmonary TB in Belarus: a nationwide cohort study. Public Heal Panor 2019;5:412–20.
WHO. Consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. Available from: https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/
Abidi S, Achar J, Neino MMA, et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J 2020;55:1901467.
Ahmad Khan F, Salim MAH, du Cros P, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J 2017;50:1700061.
Rageade F, Picot N, Blanc-Michaud A, et al. Performance of solid and liquid culture media for the detection of Mycobacterium tuberculosis in clinical materials: Meta-analysis of recent studies. Eur J Clin Microbiol Infect Dis 2014;33:867–70.

How to Cite

Avaliani, Teona, Yuliia Sereda, Hayk Davtyan, Nestani Tukvadze, Tamar Togonidze, Nana Kiria, Olga Denisiuk, Ogtay Gozalov, Sevim Ahmedov, and Arax Hovhannesyan. 2021. “Effectiveness and Safety of Fully Oral Modified Shorter Treatment Regimen for Multidrug-Resistant Tuberculosis in Georgia, 2019-2020”. Monaldi Archives for Chest Disease 91 (1). https://doi.org/10.4081/monaldi.2021.1679.